Vertex Pharmaceuticals (WBO:VRTX) Common Stock: €2 Mil (As of Mar. 2026)


WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
85 GF Score
Price €460.55
GF Value €439.23
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Common Stock?

Vertex Pharmaceuticals WBO:VRTX +1.43% 85 Common Stock is €2 Mil as of Mar. 2026. GuruFocus rates WBO:VRTX with a GF Score™ of 85/100 and a GF Value™ of €439.23 (Fairly Valued). The stock has 6 warning signs investors should review.

Vertex Pharmaceuticals's quarterly common stock increased from Sep. 2025 (€2 Mil) to Dec. 2025 (€2 Mil) and increased from Dec. 2025 (€2 Mil) to Mar. 2026 (€2 Mil).

Vertex Pharmaceuticals's annual common stock increased from Dec. 2023 (€2 Mil) to Dec. 2024 (€2 Mil) but then declined from Dec. 2024 (€2 Mil) to Dec. 2025 (€2 Mil).

Vertex Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Common Stock Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.21 2.45 2.38 2.48 2.14

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.41 2.25 2.13 2.14 2.16
WBO:VRTX
85GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €2 Mil mean?
Vertex Pharmaceuticals (WBO:VRTX) has a Common Stock of €2 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Common Stock too high?
Vertex Pharmaceuticals' current Common Stock is €2 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Common Stock compare to REGN and ALNY?
Vertex Pharmaceuticals' Common Stock of €2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Common Stock is €2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €439.23, compared to a current price of €460.55 — trading 4.9% above its estimated fair value. The current Common Stock is €2 Mil. Vertex Pharmaceuticals' overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current Common Stock is €2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued. The current stock price of €460.55 is trading 4.9% above its estimated GF Value™ of €439.23. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • Common Stock: €2 Mil
  • GF Value™: €439.23 vs. price of €460.55 (4.9% above fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
85GF Score

Get the complete analysis for WBO:VRTX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€460.55
Price
€439.23
GF Value